Could the authors elaborate on how the bioactive fraction’s stability was assessed? Given that secondary metabolites can degrade under certain conditions, understanding their stability would be crucial for our ongoing project in pharmaceutical applications.
While molecular docking supports the inhibitory potential of 4,7-dihydroxycoumarin and 5-nitro-2-naphthylamine, was any experimental validation (e.g., enzyme kinetics or IC50 determination) performed to confirm these compounds’ direct role in AChE inhibition?